INDP EBITDA | Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. (INDP) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$1.81M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.16M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.65M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$4.46M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$1.81M	(m)	(m)	(m)	(m)	-$1.93M*	(m)	$363.13K	(m)	(m)
2026-03-31	Reported	(m)	-$2.16M	(m)	(m)	(m)	(m)	-$7.01M	(m)	$491.13K	(m)	(m)
2025-09-30	Reported	(m)	-$2.65M	(m)	(m)	(m)	(m)	-$2.57M*	(m)	$1.52M	(m)	(m)
2025-06-30	Reported	(m)	-$4.46M	(m)	(m)	(m)	(m)	-$4.02M*	(m)	$2.17M	(m)	(m)
2025-03-31	Reported	(m)	-$4.57M	(m)	(m)	(m)	(m)	-$5.05M	(m)	$2.81M	(m)	(m)
2024-09-30	Reported	(m)	-$3.14M	(m)	(m)	(m)	(m)	-$2.51M*	(m)	$1.47M	(m)	(m)
2024-06-30	Reported	(m)	-$4.11M	(m)	(m)	(m)	(m)	-$2.48M*	(m)	$1.71M	(m)	(m)
2024-03-31	Reported	(m)	-$3.94M	(m)	(m)	(m)	(m)	-$3.94M	(m)	$1.59M	(m)	(m)
2023-09-30	Reported	(m)	-$4.25M	(m)	(m)	(m)	(m)	-$3.73M*	(m)	$2.23M	(m)	(m)
2023-06-30	Reported	(m)	-$3.50M	(m)	(m)	(m)	(m)	-$2.11M*	(m)	$1.48M	(m)	(m)
2023-03-31	Reported	(m)	-$4.46M	(m)	(m)	(m)	(m)	-$4.96M	(m)	$1.88M	(m)	(m)
2022-09-30	Reported	(m)	-$3.55M	(m)	(m)	(m)	(m)	-$4.60M*	(m)	$1.61M	(m)	(m)
2022-06-30	Reported	(m)	-$3.87M	(m)	(m)	(m)	(m)	-$3.15M*	(m)	$1.51M	(m)	(m)
2022-03-31	Reported	(m)	-$3.40M	(m)	(m)	(m)	(m)	-$3.12M	(m)	$1.30M	(m)	(m)
2021-09-30	Reported	(m)	-$3.37M	(m)	(m)	(m)	$1.65K*	-$5.63M*	(m)	$697.67K	(m)	(m)
2021-06-30	Reported	(m)	-$528.64K	(m)	(m)	(m)	(m)	-$1.29M*	(m)	$391.12K	(m)	$13.00K
2021-03-31	Reported	(m)	-$613.98K	(m)	(m)	(m)	(m)	-$825.58K	(m)	$489.72K	(m)	(m)
2020-09-30	Reported	(m)	-$1.55M	(m)	(m)	(m)	(m)	$4.45M*	(m)	$1.35M	(m)	(m)
2020-06-30	Reported	(m)	-$2.90M	(m)	(m)	(m)	(m)	(m)	(m)	$1.27M	(m)	$46.00K

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$19.83M	(m)	(m)	(m)	(m)	-$14.82M	(m)	$9.34M	(m)	$1.72K
2024-12-31	Reported	(m)	-$15.37M	(m)	(m)	(m)	(m)	-$12.32M	(m)	$7.25M	(m)	$1.70K
2023-12-31	Reported	(m)	-$16.38M	(m)	(m)	(m)	(m)	-$13.41M	(m)	$7.62M	(m)	$2.45K
2022-12-31	Reported	(m)	-$14.91M	(m)	(m)	(m)	(m)	-$13.08M	(m)	$6.32M	(m)	$30.00
2021-12-31	Reported	(m)	-$7.73M	(m)	(m)	(m)	$3.85K	-$11.29M	(m)	$2.52M	(m)	$1.65K
2020-12-31	Reported	(m)	-$3.60M	(m)	(m)	(m)	(m)	-$3.32M	(m)	$2.66M	(m)	$800.00

Stock Name	Country	Market Cap	PE Ratio
CRESCENT BIOPHARMA, INC. (CBIO)	United States	$0.529B	-5.20
Evolus, Inc. (EOLS)	United States	$0.519B	-13.32
ARVINAS, INC. (ARVN)	United States	$0.510B	58.38
PUMA BIOTECHNOLOGY, INC. (PBYI)	United States	$0.507B	15.53
Phathom Pharmaceuticals, Inc. (PHAT)	United States	$0.572B	-8.76
CAPRICOR THERAPEUTICS, INC. (CAPR)	United States	$0.499B	-10.81
Ovid Therapeutics Inc. (OVID)	United States	$0.487B	-14.41
ASSEMBLY BIOSCIENCES, INC. (ASMB)	United States	$0.481B	-13,053.96
Altimmune, Inc. (ALT)	United States	$0.593B	-6.43
Monopar Therapeutics (MNPR)	United States	$0.598B	-34.82